We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1), in development for the treatment of acute hepatic porphyria (AHP).
The MAA was supported by data from the pivotal ENVISION phase III study. In the study, givosiran met the primary efficacy endpoint, with a 74% mean reduction relative to placebo in the annualized rate of composite porphyria attacks. There was a corresponding 90% median reduction in composite annualized attack rate (AAR), with a median AAR of 1.0 in givosiran patients compared with that of 10.7 in placebo patients. In the trial, 50% of givosiran-treated patients were attack free during the six-month treatment period compared to 16.3% of placebo-treated patients.
Givosiran previously received Breakthrough Therapy designation and Orphan Drug status from the FDA for AHP. The drug has also been granted Priority Medicines (PRIME) designation and Orphan Drug status by the EMA for the same.
In June 2019, the company also completed the rolling submission of a new drug application (NDA) to the FDA for givosiran in AHP.
Shares of Alnylam have declined 1.3% year to date against the industry’s growth of 7.4%.
We remind investors that Onpattro, a first-of-its-kind RNAi therapeutic, is the company’s only approved drug. It is also the only FDA-approved drug for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
The company also has other candidates in its pipeline. Alnylam along with partner The Medicine Company is evaluating inclisiran in phase III ORION studies for hypercholesterolemia.
Alnylam’s expertise in RNAi therapeutics and broad intellectual property estate have allowed it to enter collaborations with leading pharmaceutical and life sciences companies, including Ionis Pharmaceuticals, Novartis (NVS - Free Report) , Roche (RHHBY - Free Report) , Takeda, Merck and Sanofi’s specialty care global business unit, Genzyme, among others.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Image: Bigstock
Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1), in development for the treatment of acute hepatic porphyria (AHP).
The MAA was supported by data from the pivotal ENVISION phase III study. In the study, givosiran met the primary efficacy endpoint, with a 74% mean reduction relative to placebo in the annualized rate of composite porphyria attacks. There was a corresponding 90% median reduction in composite annualized attack rate (AAR), with a median AAR of 1.0 in givosiran patients compared with that of 10.7 in placebo patients. In the trial, 50% of givosiran-treated patients were attack free during the six-month treatment period compared to 16.3% of placebo-treated patients.
Givosiran previously received Breakthrough Therapy designation and Orphan Drug status from the FDA for AHP. The drug has also been granted Priority Medicines (PRIME) designation and Orphan Drug status by the EMA for the same.
In June 2019, the company also completed the rolling submission of a new drug application (NDA) to the FDA for givosiran in AHP.
Shares of Alnylam have declined 1.3% year to date against the industry’s growth of 7.4%.
We remind investors that Onpattro, a first-of-its-kind RNAi therapeutic, is the company’s only approved drug. It is also the only FDA-approved drug for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
The company also has other candidates in its pipeline. Alnylam along with partner The Medicine Company is evaluating inclisiran in phase III ORION studies for hypercholesterolemia.
Alnylam’s expertise in RNAi therapeutics and broad intellectual property estate have allowed it to enter collaborations with leading pharmaceutical and life sciences companies, including Ionis Pharmaceuticals, Novartis (NVS - Free Report) , Roche (RHHBY - Free Report) , Takeda, Merck and Sanofi’s specialty care global business unit, Genzyme, among others.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote
Zacks Rank
Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>